


Attorney Docket No.: 3951.224-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of: Thim et al.

Serial No.: 09/528,644

Group Art Unit: 1647

Filed: March 20, 2000

Examiner: David Romeo

Confirmation No: 5698

For: Human Spasmolytic Polypeptide in Glycosylated Form

RECEIVED  
JAN 03 2001  
TECH CENTER 1600/2900

AMENDMENT NO FEE TRANSMITTAL

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application.

No fee is required for this Amendment. Please charge any additional fee to  
Novo Nordisk of North America, Inc., Deposit Account No. 14-1447.

Respectfully submitted,

Date: October 22, 2001

Richard W. Bork  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE